Cargando…
Cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy – a prospective analysis
BACKGROUND: Biomarkers represent a potential tool to identify individuals at risk for anthracycline-induced cardiotoxicity (AICT) prior to symptom onset or left ventricular dysfunction. METHODS: This study examined the levels of cardiac and noncardiac biomarkers before, after the last dose of, and 3...
Autores principales: | Dean, Matthew, Kim, Min Jung, Dimauro, Sharon, Tannenbaum, Susan, Graham, Garth, Liang, Bruce T., Kim, Agnes S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133897/ https://www.ncbi.nlm.nih.gov/pubmed/37106424 http://dx.doi.org/10.1186/s40959-023-00174-1 |
Ejemplares similares
-
Cardiac Evaluation and Monitoring of Patients Undergoing Noncardiac Surgery
por: Rafiq, Arsalan, et al.
Publicado: (2017) -
Cardiac Biomarkers Predicting MACE in Patients Undergoing Noncardiac Surgery: A Meta-Analysis
por: Zhang, Li-Jun, et al.
Publicado: (2019) -
RBL2 Regulates Cardiac Sensitivity to Anthracycline Chemotherapy
por: Xia, Peng, et al.
Publicado: (2023) -
Prevalence of Noncardiac Findings in Patients Undergoing Cardiac Magnetic Resonance Imaging
por: May, Christopher W., et al.
Publicado: (2012) -
Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy
por: Broeyer, F. J. F., et al.
Publicado: (2008)